Gabriel Jeremy Pascal

Mr. Gabriel Jeremy Pascal

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
DMDipon K. Mondal
Dipon K. Mondal
CXChristopher Xie
Christopher Xie
GPGabriel Jeremy Pascal
Gabriel Jeremy Pascal
SBSimone Buraschi
Simone Buraschi
RIRenato V. Iozzo
Renato V. Iozzo
The complex interplay between malignant cells and the cellular and molecular components of the tumor stroma is a key aspect of cancer growth and development. These tumor–host interactions are often affected by soluble bioactive molecules such as proteoglycans. Decorin, an archetypical small leucine-rich proteoglycan primarily expressed by stromal cells, affects cancer growth in its soluble form by interacting with several receptor tyrosine kinases (RTK). Overall, decorin leads to a context-dependent and protracted cessation of oncogenic RTK activity by attenuating their ability to drive a prosurvival program and to sustain a proangiogenic network. Through an unbiased transcriptomic analysis using deep RNAseq, we identified that decorin down-regulated a cluster of tumor-associated genes involved in lymphatic vessel (LV) development when systemically delivered to mice harboring breast carcinoma allografts. We found that Lyve1 and Podoplanin, two established markers of LVs, were markedly suppressed at both the mRNA and protein levels, and this suppression correlated with a significant reduction in tumor LVs. We further identified that soluble decorin, but not its homologous proteoglycan biglycan, inhibited LV sprouting in an ex vivo 3D model of lymphangiogenesis. Mechanistically, we found that decorin interacted with vascular endothelial growth factor receptor 3 (VEGFR3), the main lymphatic RTK, and its activity was required for the decorin-mediated block of lymphangiogenesis. Finally, we identified that Lyve1 was in part degraded via decorin-evoked autophagy in a nutrient- and energy-independent manner. These findings implicate decorin as a biological factor with antilymphangiogenic activity and provide a potential therapeutic agent for curtailing breast cancer growth and metastasis.

29 June 2024 in Proteoglycan Research
Verified
Journal Article
Open access
Maurizio MongiatMaurizio Mongiat
Maurizio Mongiat
GPGabriel Jeremy Pascal
Gabriel Jeremy Pascal
EPEvelina Poletto
Evelina Poletto
DWDavion M. Williams
Davion M. Williams
RIRenato V. Iozzo
Renato V. Iozzo
Antiangiogenic therapy is an established method for the treatment of several cancers and vascular‐related diseases. Most of the agents employed target the vascular endothelial growth factor A, the major cytokine stimulating angiogenesis. However, the efficacy of these treatments is limited by the onset of drug resistance. Therefore, it is of fundamental importance to better understand the mechanisms that regulate angiogenesis and the microenvironmental cues that play significant role and influence patient treatment and outcome. In this context, here we review the importance of the three basement membrane (BM) heparan sulfate proteoglycans (HSPGs), namely perlecan, agrin, and collagen XVIII. These HSPGs are abundantly expressed in the vasculature and, due to their complex molecular architecture, they interact with multiple endothelial cell receptors, deeply affecting their function. Under normal conditions, these proteoglycans exert proangiogenic functions. However, in pathological conditions such as cancer and inflammation, extracellular matrix remodeling leads to the degradation of these large precursor molecules and the liberation of bioactive processed fragments displaying potent angiostatic activity. These unexpected functions have been demonstrated for the C‐terminal fragments of perlecan and collagen XVIII, endorepellin, and endostatin. These bioactive fragments can also induce autophagy in vascular endothelial cells which contributes to angiostasis. Overall, BM proteoglycans deeply affect angiogenesis counterbalancing proangiogenic signals during tumor progression and represent possible means to develop new prognostic biomarkers and novel therapeutic approaches for the treatment of solid tumors.

8 January 2025 in Proteoglycan Research
Verified
Journal Article
Open access
SBSimone Buraschi
Simone Buraschi
GPGabriel Jeremy Pascal
Gabriel Jeremy Pascal
FLFederico Liberatore
Federico Liberatore
RIRenato V. Iozzo
Renato V. Iozzo
Solid tumors present a formidable challenge in oncology, necessitating innovative approaches to improve therapeutic outcomes. Proteoglycans, multifaceted molecules within the tumor microenvironment, have garnered attention due to their diverse roles in cancer progression. Their unique ability to interact with specific membrane receptors, growth factors, and cytokines provides a promising avenue for the development of recombinant proteoglycan‐based therapies that could enhance the precision and efficacy of cancer treatment. In this study, we performed a comprehensive analysis of the proteoglycan gene landscape in human breast carcinomas. Leveraging the available wealth of genomic and clinical data regarding gene expression in breast carcinoma and using a machine learning model, we identified a unique gene expression signature composed of five proteoglycans differentially modulated in the tumor tissue: Syndecan‐1 and asporin (upregulated) and decorin, PRELP and podocan (downregulated). Additional query of the breast carcinoma data revealed that serglycin, previously shown to be increased in breast carcinoma patients and mouse models and to correlate with a poor prognosis, was indeed decreased in the vast majority of breast cancer patients and its levels inversely correlated with tumor progression and invasion. This proteoglycan gene signature could provide novel diagnostic capabilities in breast cancer biology and highlights the need for further utilization of publicly available datasets for the clinical validation of preclinical experimental results.

31 March 2024 in Cancers
Verified
Journal Article
Open access
PDF file
LBLaura Been
Laura Been
AHAmanda Halliday
Amanda Halliday
SBSarah M. Blossom
Sarah M. Blossom
EBElena M. Bien
Elena M. Bien
ABAnya G. Bernhard
Anya G. Bernhard
MKMary Ellen Kelly
Mary Ellen Kelly
Tamoxifen, a selective estrogen receptor modulator (SERM), is commonly used as an adjuvant drug therapy for estrogen-receptor-positive breast cancers. Though effective at reducing the rate of cancer recurrence, patients often report unwanted cognitive and affective side effects. Despite this, the impacts of chronic tamoxifen exposure on the brain are poorly understood, and rodent models of tamoxifen exposure do not replicate the chronic oral administration seen in patients. We, therefore, used long-term ad lib consumption of medicated food pellets to model chronic tamoxifen exposure in a clinically relevant way. Adult female Long-Evans Hooded rats consumed tamoxifen-medicated food pellets for approximately 12 weeks, while control animals received standard chow. At the conclusion of the experiment, blood and brain samples were collected for analyses. Blood tamoxifen levels were measured using a novel ultra-performance liquid chromatography–tandem mass spectrometry assay, which found that this administration paradigm produced serum levels of tamoxifen similar to those in human patients. In the brain, brain-derived neurotrophic factor (BDNF) was visualized in the hippocampus using immunohistochemistry. Chronic oral tamoxifen treatment resulted in a decrease in BDNF expression across several regions of the hippocampus. These findings provide a novel method of modeling and measuring chronic oral tamoxifen exposure and suggest a putative mechanism by which tamoxifen may cause cognitive and behavioral changes reported by patients.

30 September 2025 in Proteoglycan Research
Verified
Journal Article
Open access
GPGabriel Jeremy Pascal
Gabriel Jeremy Pascal
DMDipon K. Mondal
Dipon K. Mondal
SKSadie Kim
Sadie Kim
CXChristopher Xie
Christopher Xie
DSDevanarayanan Siva Sankar
Devanarayanan Siva Sankar
RIRenato V. Iozzo
Renato V. Iozzo
The lymphatic system is critical to the body's immune and circulatory system, and lymphangiogenesis, the development of new lymphatic vessels from pre‐existing ones, is a significant process capitalized upon by cancer during tumorigenesis. Decorin is a small leucine‐rich proteoglycan which we have previously shown to be anti‐tumorigenic and a suppressor of lymphangiogenesis. We have also shown that decorin exercises its anticancer properties through its ability to evoke autophagy. Through a comprehensive and unbiased proteomic analysis, we explored the implications of decorin exposure on protein expression within mouse lymphatic endothelial cells. We discovered that decorin enriches several protein pathways, notably proteasomal degradation and lysosomal pathways. Several proteins within these pathways such as lysosome associated membrane protein 1 (Lamp1) and Neural precursor cell expressed developmentally downregulated protein 8 (Nedd8) were differentially regulated following decorin treatment. These proteins and their functional pathways should be considered therapeutic targets and emerge as candidates for further exploration within the context of decorin and cancer suppression.

20 October 2026 in Proteoglycan Research
Verified
Journal Article
Open access
PDF file
GPGabriel Jeremy Pascal
Gabriel Jeremy Pascal
SKSadie Kim
Sadie Kim
CXChristopher Xie
Christopher Xie
MDMaria Danial
Maria Danial
IBIris Barone
Iris Barone
RIRenato V. Iozzo
Renato V. Iozzo
Small leucine‐rich proteoglycans (SLRPs) are a well‐known family of extracellular matrix (ECM) molecules. They consist of five classes with 18 different protein cores originally recognized as having a physically supportive component to the extracellular structure and tissue integrity. There has been a significant conceptual shift from the original paradigm as mere contributors to ECM structure to the current concept of bioactive signaling molecules. Over the past three decades, SLRPs have evolved into critical modulators of signaling events in cells by contributing to the regulation of receptor activity and intercellular communication. They also affect key biological processes such as tissue remodeling, inflammation, and autophagy. Through interactions with receptor tyrosine kinases, integrins, and growth factors they regulate signaling pathways involved in cell proliferation, survival, and migration. These biological interactions allow for the regulation of cellular function and microenvironment homeostasis in a context dependent manner. In this review, we will comprehensively assess all 18 SLRPs in their relation to cancer biology and analyze how they contribute to the initiation and development of tumors and the regulation of stroma. Abnormal SLRP signaling will disturb the ECM cellular interactions and responses, which may result in oncogenic progression.